Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PER.AX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: July 30, 2025
Report Source: 2025 2nd Quarter Report
Percheron Therapeutics Ltd. Stock Analysis PER.AX
Australia Health Care Nano Cap Report: Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.
Read More Percheron Therapeutics Ltd (PER.AX) Chart
Key Statistics of Percheron Therapeutics Ltd (PER.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.00Volume
1.23MP/E Ratio (TTM)
-52 Week Range
Market Cap
6.09MAvg. Volume
1.64MDividend Yield
-Financial Metrics & Statements of Percheron Therapeutics Ltd (PER.AX)
FAQ's for Percheron Therapeutics Ltd (PER.AX)
- According to Musaffa’s Shariah screening methodology, Percheron Therapeutics Ltd (PER.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Percheron Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Percheron Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Percheron Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Percheron Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Percheron Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.